TENAYA THERAPEUTICS I

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8 2024 15:05:01 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Research Leadership Updates

27 6 2024 16:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

18 6 2024 15:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

14 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

02 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

18 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

18 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

27 2 2024 15:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

26 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Underwritten Offering

08 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

21 11 2023 15:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

08 11 2023 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

26 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

09 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

05 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

02 10 2023 16:30:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

21 9 2023 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

31 8 2023 15:05:00 提供 Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

09 8 2023 15:05:01 提供 Nasdaq GlobeNewswire